The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011.
Fiche publication
Date publication
juin 2013
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MERLIN Jean-Louis
Tous les auteurs :
Lièvre A, Artru P, Guiu M, Laurent-Puig P, Merlin JL, Sabourin JC, Viguier J, Bastie A, Seronde A, Ducreux M
Lien Pubmed
Résumé
The detection of KRAS mutations is mandatory to initiate an anti-epidermal growth factor receptor (EGFR) antibody in the treatment of metastatic colorectal carcinoma (mCRC).
Mots clés
Adult, Aged, Antineoplastic Agents, therapeutic use, Colonic Neoplasms, drug therapy, DNA Mutational Analysis, utilization, Female, France, Genes, ras, genetics, Genetic Testing, utilization, Genotype, Humans, Male, Middle Aged, Mutation, genetics, Neoplasm Metastasis, Practice Patterns, Physicians', statistics & numerical data, Receptor, Epidermal Growth Factor, antagonists & inhibitors, Rectal Neoplasms, drug therapy, Referral and Consultation, statistics & numerical data, Retrospective Studies, Time Factors
Référence
Eur. J. Cancer. 2013 Jun;49(9):2126-33